Ocular Therapeutix, Inc (OCUL) stock
OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)
Close on Nov 17, 2026Market cap $1.32BP/E –Yield –
Ocular Therapeutix total assets
Total assets on the balance sheet at the end of each period.
Ocular Therapeutix's total assets was $671.32M at Jun 30, 2026. For fiscal 2025 it was $808.06M, up 76.5% from the year before. Over ten years it grew 22.0% a year on average. The highest annual figure on record is $808.06M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $808.06M | +76.5% |
| FY2024 | Dec 31, 2024 | $457.94M | +81.7% |
| FY2023 | Dec 31, 2023 | $252.06M | +68.8% |
| FY2022 | Dec 31, 2022 | $149.29M | -27.1% |
| FY2021 | Dec 31, 2021 | $204.89M | -21.8% |
| FY2020 | Dec 31, 2020 | $261.86M | +232.6% |
| FY2019 | Dec 31, 2019 | $78.74M | +7.8% |
| FY2018 | Dec 31, 2018 | $73.04M | +31.8% |
| FY2017 | Dec 31, 2017 | $55.43M | -26.0% |
| FY2016 | Dec 31, 2016 | $74.94M | -32.1% |
| FY2015 | Dec 31, 2015 | $110.31M | +41.1% |
| FY2014 | Dec 31, 2014 | $78.19M | +308.4% |
| FY2013 | Dec 31, 2013 | $19.15M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $671.32M | +48.7% |
| Q1 FY2026 | Mar 31, 2026 | $732.53M | +80.5% |
| Q4 FY2025 | Dec 31, 2025 | $808.06M | +76.5% |
| Q3 FY2025 | Sep 30, 2025 | $410.88M | -16.2% |
| Q2 FY2025 | Jun 30, 2025 | $451.33M | -12.7% |
| Q1 FY2025 | Mar 31, 2025 | $405.92M | -24.7% |
| Q4 FY2024 | Dec 31, 2024 | $457.94M | +81.7% |
| Q3 FY2024 | Sep 30, 2024 | $490.37M | +202.0% |
| Q2 FY2024 | Jun 30, 2024 | $517.09M | +321.9% |
| Q1 FY2024 | Mar 31, 2024 | $538.95M | +319.2% |
| Q4 FY2023 | Dec 31, 2023 | $252.06M | +68.8% |
| Q3 FY2023 | Sep 30, 2023 | $162.38M | +2.4% |
| Q2 FY2023 | Jun 30, 2023 | $122.56M | -29.2% |
| Q1 FY2023 | Mar 31, 2023 | $128.57M | -31.5% |
| Q4 FY2022 | Dec 31, 2022 | $149.29M | -27.1% |
| Q3 FY2022 | Sep 30, 2022 | $158.58M | -27.2% |
| Q2 FY2022 | Jun 30, 2022 | $173.07M | -25.0% |
| Q1 FY2022 | Mar 31, 2022 | $187.62M | -22.8% |
| Q4 FY2021 | Dec 31, 2021 | $204.89M | -21.8% |
| Q3 FY2021 | Sep 30, 2021 | $217.74M | +121.7% |
| Q2 FY2021 | Jun 30, 2021 | $230.71M | +115.1% |
| Q1 FY2021 | Mar 31, 2021 | $243.04M | +233.6% |
| Q4 FY2020 | Dec 31, 2020 | $261.86M | +232.6% |
| Q3 FY2020 | Sep 30, 2020 | $98.22M | +10.7% |
| Q2 FY2020 | Jun 30, 2020 | $107.26M | +19.5% |
| Q1 FY2020 | Mar 31, 2020 | $72.86M | -28.2% |
| Q4 FY2019 | Dec 31, 2019 | $78.74M | +7.8% |
| Q3 FY2019 | Sep 30, 2019 | $88.71M | +26.2% |
| Q2 FY2019 | Jun 30, 2019 | $89.74M | +27.4% |
| Q1 FY2019 | Mar 31, 2019 | $101.49M | +32.3% |
| Q4 FY2018 | Dec 31, 2018 | $73.04M | +31.8% |
| Q3 FY2018 | Sep 30, 2018 | $70.27M | +9.1% |
| Q2 FY2018 | Jun 30, 2018 | $70.46M | -11.6% |
| Q1 FY2018 | Mar 31, 2018 | $76.69M | -15.4% |
| Q4 FY2017 | Dec 31, 2017 | $55.43M | -26.0% |
| Q3 FY2017 | Sep 30, 2017 | $64.40M | -21.8% |
| Q2 FY2017 | Jun 30, 2017 | $79.68M | – |
| Q1 FY2017 | Mar 31, 2017 | $90.70M | – |
| Q4 FY2016 | Dec 31, 2016 | $74.94M | – |
| Q3 FY2016 | Sep 30, 2016 | $82.35M | – |
See a number that looks wrong?